Due to our sample size, study design, and number of clinically relevant matching variables, we opted for a simple, unadjusted analysis to inform a conclusion as to whether the technique is sufficiently safe to proceed to phase two trials to test efficacy
[DOI] [PubMed] [Google Scholar] 3.Peeters A., Barendregt J.J., Willekens F., Mackenbach J.P., Mamun A.A., Bonneux L
Will subtle scars appear that todays short trials are unable to reveal
All study participants gave written informed consent and were informed about the study (EK Nr: 1023/2024)
It may be that we should continue treatment in people who have had cardiovascular disease, even if they dont lose as much weight as we would like. This is already the case in the United States where, in March 2024, the US Food and Drug Administration approved Wegovy to treat adults with cardiovascular disease who also have obesity or are overweight but without diabetes mellitus
Browse related peptide guides Dr Rimas Geiga Learn more about the clinics medical adviser with interests in metabolism, nutrition and healthy ageing